{"id": "article-21383_0", "title": "Ethambutol -- Continuing Education Activity", "content": "Ethambutol is a bacteriostatic drug that inhibits cell wall synthesis and is used to manage and treat tuberculosis (TB). The mechanism of action, dosing considerations, pharmacokinetics, adverse event profiles, contraindications, boxed warnings, and monitoring strategies are highlighted within a multi-drug\u00a0treatment. In particular, the severe adverse drug reaction relating to optic neuropathy is discussed, with relevant interventions mentioned.\u00a0New drugs like bedaquiline offer promise in improving\u00a0TB\u00a0outcomes, but addressing pharmacy challenges and ensuring interprofessional collaboration remains crucial for effective patient management with ethambutol therapy. Given the emergence of ethambutol-resistant\u00a0TB strains, the emphasis on contraindicated single regimen use is important.", "contents": "Ethambutol -- Continuing Education Activity. Ethambutol is a bacteriostatic drug that inhibits cell wall synthesis and is used to manage and treat tuberculosis (TB). The mechanism of action, dosing considerations, pharmacokinetics, adverse event profiles, contraindications, boxed warnings, and monitoring strategies are highlighted within a multi-drug\u00a0treatment. In particular, the severe adverse drug reaction relating to optic neuropathy is discussed, with relevant interventions mentioned.\u00a0New drugs like bedaquiline offer promise in improving\u00a0TB\u00a0outcomes, but addressing pharmacy challenges and ensuring interprofessional collaboration remains crucial for effective patient management with ethambutol therapy. Given the emergence of ethambutol-resistant\u00a0TB strains, the emphasis on contraindicated single regimen use is important."}
{"id": "article-21383_1", "title": "Ethambutol -- Continuing Education Activity", "content": "This activity will highlight other key factors, such as off-label uses, dosing, and monitoring, pertinent to healthcare team members treating patients with tuberculosis and related conditions. The interprofessional team, including infectious disease specialists or ophthalmologists in complicated cases, is equipped with comprehensive knowledge to enhance patient care during therapy with ethambutol.", "contents": "Ethambutol -- Continuing Education Activity. This activity will highlight other key factors, such as off-label uses, dosing, and monitoring, pertinent to healthcare team members treating patients with tuberculosis and related conditions. The interprofessional team, including infectious disease specialists or ophthalmologists in complicated cases, is equipped with comprehensive knowledge to enhance patient care during therapy with ethambutol."}
{"id": "article-21383_2", "title": "Ethambutol -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action of ethambutol in comparison to other medications for tuberculosis. Evaluate\u00a0the potential adverse effects of ethambutol with emphasis on optic neuropathy. Determine\u00a0the appropriate monitoring for patients\u00a0undergoing therapy with ethambutol. Implement effective collaboration among interprofessional team members to improve treatment efficacy for patients who benefit from treatment with ethambutol. Access free multiple choice questions on this topic.", "contents": "Ethambutol -- Continuing Education Activity. Objectives: Identify the mechanism of action of ethambutol in comparison to other medications for tuberculosis. Evaluate\u00a0the potential adverse effects of ethambutol with emphasis on optic neuropathy. Determine\u00a0the appropriate monitoring for patients\u00a0undergoing therapy with ethambutol. Implement effective collaboration among interprofessional team members to improve treatment efficacy for patients who benefit from treatment with ethambutol. Access free multiple choice questions on this topic."}
{"id": "article-21383_3", "title": "Ethambutol -- Indications", "content": "Ethambutol has been\u00a0utilized to treat tuberculosis (TB) since the 1960s. The original formulation of\u00a0ethambutol was a racemic mixture of\u00a0the L and D forms. The D form of ethambutol was known for\u00a0therapeutic effect; however, the L form was known for\u00a0toxicity and, hence, discontinued. [1]", "contents": "Ethambutol -- Indications. Ethambutol has been\u00a0utilized to treat tuberculosis (TB) since the 1960s. The original formulation of\u00a0ethambutol was a racemic mixture of\u00a0the L and D forms. The D form of ethambutol was known for\u00a0therapeutic effect; however, the L form was known for\u00a0toxicity and, hence, discontinued. [1]"}
{"id": "article-21383_4", "title": "Ethambutol -- Indications -- FDA-Approved Indications", "content": "Ethambutol is used for the treatment of pulmonary tuberculosis.\u00a0The medication should not be used\u00a0as a single regimen but rather in tandem with at least\u00a01 antitubercular drug, such as isoniazid.\u00a0Ethambutol is effective against Mycobacterium tuberculosis strains\u00a0but\u00a0less effective against viruses, fungi, or other bacteria.\u00a0Antitubercular medications used with\u00a0ethambutol include cycloserine, ethionamide, pyrazinamide, viomycin, isoniazid, aminosalicylic acid, and streptomycin. [2]", "contents": "Ethambutol -- Indications -- FDA-Approved Indications. Ethambutol is used for the treatment of pulmonary tuberculosis.\u00a0The medication should not be used\u00a0as a single regimen but rather in tandem with at least\u00a01 antitubercular drug, such as isoniazid.\u00a0Ethambutol is effective against Mycobacterium tuberculosis strains\u00a0but\u00a0less effective against viruses, fungi, or other bacteria.\u00a0Antitubercular medications used with\u00a0ethambutol include cycloserine, ethionamide, pyrazinamide, viomycin, isoniazid, aminosalicylic acid, and streptomycin. [2]"}
{"id": "article-21383_5", "title": "Ethambutol -- Indications -- Off-Label Uses", "content": "The American Thoracic Society/European Society of Clinical Microbiology and Infectious Diseases/European Respiratory Society/Infectious Diseases Society of America guideline for nontuberculous mycobacterial pulmonary disease endorses ethambutol for Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi. [3] Few imaging techniques can directly visualize tuberculosis in the body. Although not widely documented, technetium-99m ethambutol scintigraphy is emerging as a promising method. In a recent case, a patient with an iliopsoas abscess demonstrated increased uptake on Tc-99m ethambutol scintigraphy, later confirmed tubercular through pus analysis. This underscores the potential of Tc-99m ethambutol scintigraphy as a sensitive\u00a0tool\u00a0for detecting tubercular lesions, offering valuable insights for treatment and monitoring. [4]", "contents": "Ethambutol -- Indications -- Off-Label Uses. The American Thoracic Society/European Society of Clinical Microbiology and Infectious Diseases/European Respiratory Society/Infectious Diseases Society of America guideline for nontuberculous mycobacterial pulmonary disease endorses ethambutol for Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi. [3] Few imaging techniques can directly visualize tuberculosis in the body. Although not widely documented, technetium-99m ethambutol scintigraphy is emerging as a promising method. In a recent case, a patient with an iliopsoas abscess demonstrated increased uptake on Tc-99m ethambutol scintigraphy, later confirmed tubercular through pus analysis. This underscores the potential of Tc-99m ethambutol scintigraphy as a sensitive\u00a0tool\u00a0for detecting tubercular lesions, offering valuable insights for treatment and monitoring. [4]"}
{"id": "article-21383_6", "title": "Ethambutol -- Mechanism of Action", "content": "Ethambutol is one of the first lines of treatment for TB, along with rifampicin, isoniazid, and pyrazinamide. Ethambutol is considered a bacteriostatic drug, interfering with the biosynthesis of arabinogalactan in the cell wall, halting multiplying bacilli. [5] However, the underlying molecular mechanisms remain unclear. [6]", "contents": "Ethambutol -- Mechanism of Action. Ethambutol is one of the first lines of treatment for TB, along with rifampicin, isoniazid, and pyrazinamide. Ethambutol is considered a bacteriostatic drug, interfering with the biosynthesis of arabinogalactan in the cell wall, halting multiplying bacilli. [5] However, the underlying molecular mechanisms remain unclear. [6]"}
{"id": "article-21383_7", "title": "Ethambutol -- Mechanism of Action", "content": "Researchers speculate that ethambutol has synergistic effects with isoniazid (INH) against Mycobacterium tuberculosis through a transcriptional repressor of the inhA gene, a targeted gene by INH that encodes for an enoyl-acyl carrier protein reductase which is necessary for bacterial cell wall integrity. The results of a study indicate that ethambutol binds to a TetR transcriptional regulator that enhances the INH sensitivity of the inhA gene. As a result, the\u00a0bactericidal\u00a0effect of INH is increased. [7]", "contents": "Ethambutol -- Mechanism of Action. Researchers speculate that ethambutol has synergistic effects with isoniazid (INH) against Mycobacterium tuberculosis through a transcriptional repressor of the inhA gene, a targeted gene by INH that encodes for an enoyl-acyl carrier protein reductase which is necessary for bacterial cell wall integrity. The results of a study indicate that ethambutol binds to a TetR transcriptional regulator that enhances the INH sensitivity of the inhA gene. As a result, the\u00a0bactericidal\u00a0effect of INH is increased. [7]"}
{"id": "article-21383_8", "title": "Ethambutol -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Ethambutol achieves peak serum concentrations within 2 to 4 hours post-administration. Upon daily administration at this dosage over prolonged periods, serum levels remain consistent.", "contents": "Ethambutol -- Mechanism of Action -- Pharmacokinetics. Absorption: Ethambutol achieves peak serum concentrations within 2 to 4 hours post-administration. Upon daily administration at this dosage over prolonged periods, serum levels remain consistent."}
{"id": "article-21383_9", "title": "Ethambutol -- Mechanism of Action -- Pharmacokinetics", "content": "Distribution: The drug's distribution is widespread, with erythrocyte concentrations approximately twice that of plasma. Ethambutol hydrochloride diffuses readily into actively growing mycobacterium cells, contributing to therapeutic efficacy. Metabolism: The metabolism of ethambutol to an aldehyde intermediate and dicarboxylic acid is catalyzed by the alcohol dehydrogenase enzyme.", "contents": "Ethambutol -- Mechanism of Action -- Pharmacokinetics. Distribution: The drug's distribution is widespread, with erythrocyte concentrations approximately twice that of plasma. Ethambutol hydrochloride diffuses readily into actively growing mycobacterium cells, contributing to therapeutic efficacy. Metabolism: The metabolism of ethambutol to an aldehyde intermediate and dicarboxylic acid is catalyzed by the alcohol dehydrogenase enzyme."}
{"id": "article-21383_10", "title": "Ethambutol -- Mechanism of Action -- Pharmacokinetics", "content": "Excretion: Ethambutol\u00a0is eliminated primarily via renal excretion, with a smaller fraction excreted in the feces. Patients with renal insufficiency may exhibit marked drug accumulation due to impaired clearance mechanisms. [8]", "contents": "Ethambutol -- Mechanism of Action -- Pharmacokinetics. Excretion: Ethambutol\u00a0is eliminated primarily via renal excretion, with a smaller fraction excreted in the feces. Patients with renal insufficiency may exhibit marked drug accumulation due to impaired clearance mechanisms. [8]"}
{"id": "article-21383_11", "title": "Ethambutol -- Administration -- Available Dosage Forms and Strengths", "content": "Ethambutol can be administered orally and in tablet form in 400 and 100 mg doses.\u00a0Ethambutol should not be used stand-alone in initial treatment or re-treatment.\u00a0The medication\u00a0should be used in conjunction with another antitubercular drug.\u00a0Current first-line therapy for tuberculosis is a quadruple therapy of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol for\u00a02 months, followed by a 4-month continuation of isoniazid, rifampicin, and ethambutol.", "contents": "Ethambutol -- Administration -- Available Dosage Forms and Strengths. Ethambutol can be administered orally and in tablet form in 400 and 100 mg doses.\u00a0Ethambutol should not be used stand-alone in initial treatment or re-treatment.\u00a0The medication\u00a0should be used in conjunction with another antitubercular drug.\u00a0Current first-line therapy for tuberculosis is a quadruple therapy of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol for\u00a02 months, followed by a 4-month continuation of isoniazid, rifampicin, and ethambutol."}
{"id": "article-21383_12", "title": "Ethambutol -- Administration -- Initial treatment", "content": "Initial treatment for patients who have not received previous tuberculosis therapy should be administered with 15 mg/kg of body weight every 24 hours.", "contents": "Ethambutol -- Administration -- Initial treatment. Initial treatment for patients who have not received previous tuberculosis therapy should be administered with 15 mg/kg of body weight every 24 hours."}
{"id": "article-21383_13", "title": "Ethambutol -- Administration -- Re-treatment", "content": "Multidrug-resistant tuberculosis (MDR-TB) and extremely drug-resistant tuberculosis (XDR-TB) is a global issue. [9] For\u00a0patients with a history of previous tuberculosis treatment, the recommended dosage of ethambutol is 25 mg/kg administered orally daily. After 60 days of continuous therapy, the dosage should be reduced to 15 mg/kg administered orally once daily. The dosages for ethambutol, recommended by the American Thoracic Society (ATS)/Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for drug-susceptible tuberculosis, are outlined below.", "contents": "Ethambutol -- Administration -- Re-treatment. Multidrug-resistant tuberculosis (MDR-TB) and extremely drug-resistant tuberculosis (XDR-TB) is a global issue. [9] For\u00a0patients with a history of previous tuberculosis treatment, the recommended dosage of ethambutol is 25 mg/kg administered orally daily. After 60 days of continuous therapy, the dosage should be reduced to 15 mg/kg administered orally once daily. The dosages for ethambutol, recommended by the American Thoracic Society (ATS)/Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for drug-susceptible tuberculosis, are outlined below."}
{"id": "article-21383_14", "title": "Ethambutol -- Administration -- Daily regimen", "content": "For individuals weighing 40 to 55 kg:\u00a0800 mg (14.5 to 20 mg/kg) For individuals weighing 56 to 75 kg:\u00a01200 mg (16 to 21.4 mg/kg) For individuals weighing 76 to 90 kg:\u00a01600 mg (17.8 to 21.1 mg/kg)", "contents": "Ethambutol -- Administration -- Daily regimen. For individuals weighing 40 to 55 kg:\u00a0800 mg (14.5 to 20 mg/kg) For individuals weighing 56 to 75 kg:\u00a01200 mg (16 to 21.4 mg/kg) For individuals weighing 76 to 90 kg:\u00a01600 mg (17.8 to 21.1 mg/kg)"}
{"id": "article-21383_15", "title": "Ethambutol -- Administration -- Thrice weekly regimen", "content": "For individuals weighing 40 to 55 kg:\u00a01200 mg (21.8 to 30 mg/kg) For individuals weighing 56 to 75 kg:\u00a02000 mg (26.7 to 35.7 mg/kg) For individuals weighing 76 to 90 kg:\u00a02400 mg (26.7 to 31.6 mg/kg)", "contents": "Ethambutol -- Administration -- Thrice weekly regimen. For individuals weighing 40 to 55 kg:\u00a01200 mg (21.8 to 30 mg/kg) For individuals weighing 56 to 75 kg:\u00a02000 mg (26.7 to 35.7 mg/kg) For individuals weighing 76 to 90 kg:\u00a02400 mg (26.7 to 31.6 mg/kg)"}
{"id": "article-21383_16", "title": "Ethambutol -- Administration -- Twice weekly regimen", "content": "For individuals weighing 40 to 55 kg:\u00a02000 mg (36.4 to 50 mg/kg) For individuals weighing 56 to 75 kg:\u00a02800 mg (37.3 to 50 mg/kg) For individuals weighing 76 to 90 kg:\u00a04000 mg (44.4 to 52.6 mg/kg) These dosages are calculated based on estimated lean body weight and are suitable for patients with normal renal function. [10]", "contents": "Ethambutol -- Administration -- Twice weekly regimen. For individuals weighing 40 to 55 kg:\u00a02000 mg (36.4 to 50 mg/kg) For individuals weighing 56 to 75 kg:\u00a02800 mg (37.3 to 50 mg/kg) For individuals weighing 76 to 90 kg:\u00a04000 mg (44.4 to 52.6 mg/kg) These dosages are calculated based on estimated lean body weight and are suitable for patients with normal renal function. [10]"}
{"id": "article-21383_17", "title": "Ethambutol -- Administration", "content": "Only one reported re-treatment with ethambutol was documented in a patient who previously recovered from ethambutol-induced optic neuropathy. The patient's initial treatment consisted of 22 mg/kg/day of ethambutol with rifampicin, clarithromycin, and ciprofloxacin, which eventually developed into ethambutol-induced optic neuropathy. After\u00a0clinicians\u00a0discontinued ethambutol, her visual acuity recovered while she continued her regimen. However,\u00a010 years later, the patient was diagnosed with tuberculosis again. The patient was treated with rifampicin, clarithromycin, and ethambutol at 25 mg/kg/day\u00a03 days a week. With the supplementation of copper at 2 mg daily, the patient did not show significant signs of visual change after a 14-month course regimen. [11]", "contents": "Ethambutol -- Administration. Only one reported re-treatment with ethambutol was documented in a patient who previously recovered from ethambutol-induced optic neuropathy. The patient's initial treatment consisted of 22 mg/kg/day of ethambutol with rifampicin, clarithromycin, and ciprofloxacin, which eventually developed into ethambutol-induced optic neuropathy. After\u00a0clinicians\u00a0discontinued ethambutol, her visual acuity recovered while she continued her regimen. However,\u00a010 years later, the patient was diagnosed with tuberculosis again. The patient was treated with rifampicin, clarithromycin, and ethambutol at 25 mg/kg/day\u00a03 days a week. With the supplementation of copper at 2 mg daily, the patient did not show significant signs of visual change after a 14-month course regimen. [11]"}
{"id": "article-21383_18", "title": "Ethambutol -- Administration", "content": "The results of recent\u00a0studies have assessed the administration of a dry powder inhaler using ethambutol-loaded solid lipid nanoparticles. The\u00a0dry powder inhaler\u00a0formulations consisted of spray-drying ethambutol-loaded\u00a0solid lipid nanoparticles with and without mannitol. The encapsulation efficiency was higher than 98%, and the particle size was sub-100 nm. Results have shown that dry powder inhalers using ethambutol-loaded solid lipid nanoparticles have a high potential for the direct treatment of TB. [12]", "contents": "Ethambutol -- Administration. The results of recent\u00a0studies have assessed the administration of a dry powder inhaler using ethambutol-loaded solid lipid nanoparticles. The\u00a0dry powder inhaler\u00a0formulations consisted of spray-drying ethambutol-loaded\u00a0solid lipid nanoparticles with and without mannitol. The encapsulation efficiency was higher than 98%, and the particle size was sub-100 nm. Results have shown that dry powder inhalers using ethambutol-loaded solid lipid nanoparticles have a high potential for the direct treatment of TB. [12]"}
{"id": "article-21383_19", "title": "Ethambutol -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: Hepatotoxicity, including instances of liver damage leading to fatalities, has been reported with the use of ethambutol. Conducting baseline liver function assessments and monitoring hepatic function throughout treatment is necessary.", "contents": "Ethambutol -- Administration -- Specific Patient Populations. Hepatic impairment: Hepatotoxicity, including instances of liver damage leading to fatalities, has been reported with the use of ethambutol. Conducting baseline liver function assessments and monitoring hepatic function throughout treatment is necessary."}
{"id": "article-21383_20", "title": "Ethambutol -- Administration -- Specific Patient Populations", "content": "Renal impairment: To mitigate the risk of toxicity, the dosing regimen for ethambutol must be adjusted in patients with hemodialysis or creatinine clearance below 30 mL/min. Ethambutol should be administered\u00a03 times a week instead of daily. Pregnancy considerations: Ethambutol\u00a0does not seem to have a teratogenic effect on pregnant women. [13]", "contents": "Ethambutol -- Administration -- Specific Patient Populations. Renal impairment: To mitigate the risk of toxicity, the dosing regimen for ethambutol must be adjusted in patients with hemodialysis or creatinine clearance below 30 mL/min. Ethambutol should be administered\u00a03 times a week instead of daily. Pregnancy considerations: Ethambutol\u00a0does not seem to have a teratogenic effect on pregnant women. [13]"}
{"id": "article-21383_21", "title": "Ethambutol -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: Limited evidence suggests that maternal intake of ethambutol\u00a0of 15 mg/kg daily results in minimal levels\u00a0in the\u00a0breast milk, posing low risk to infants. The\u00a0CDC advises against discouraging breastfeeding in women\u00a0being treated with ethambutol. [14]", "contents": "Ethambutol -- Administration -- Specific Patient Populations. Breastfeeding considerations: Limited evidence suggests that maternal intake of ethambutol\u00a0of 15 mg/kg daily results in minimal levels\u00a0in the\u00a0breast milk, posing low risk to infants. The\u00a0CDC advises against discouraging breastfeeding in women\u00a0being treated with ethambutol. [14]"}
{"id": "article-21383_22", "title": "Ethambutol -- Administration -- Specific Patient Populations", "content": "Pediatric patients: Ethambutol is not recommended for use in children aged under 13 due to the lack of established safety parameters.\u00a0Per IDSA/CDC/ATS guidelines, the pediatric dose for ethambutol ranges from 15 to 25 mg/kg. [2]", "contents": "Ethambutol -- Administration -- Specific Patient Populations. Pediatric patients: Ethambutol is not recommended for use in children aged under 13 due to the lack of established safety parameters.\u00a0Per IDSA/CDC/ATS guidelines, the pediatric dose for ethambutol ranges from 15 to 25 mg/kg. [2]"}
{"id": "article-21383_23", "title": "Ethambutol -- Administration -- Specific Patient Populations", "content": "Older patients: Limited data on the use of ethambutol in older patients\u00a0suggests comparable safety and tolerability to adults.\u00a0Assessing renal and hepatic function in older patients is necessary due to age-related changes that can impact the metabolism and excretion of medications.", "contents": "Ethambutol -- Administration -- Specific Patient Populations. Older patients: Limited data on the use of ethambutol in older patients\u00a0suggests comparable safety and tolerability to adults.\u00a0Assessing renal and hepatic function in older patients is necessary due to age-related changes that can impact the metabolism and excretion of medications."}
{"id": "article-21383_24", "title": "Ethambutol -- Adverse Effects -- Loss of Visual Acuity", "content": "Optic neuropathy/optic neuritis/retrobulbar neuritis Decreased visual acuity Scotoma Color blindness Visual field defect Blurred vision Peripheral neuropathy Hepatotoxicity Numbness and tingling of extremities due to peripheral neuritis Mental confusion, disorientation, and possible hallucinations Psychosis [15] [16] Patients with\u00a0impaired renal function from renal tuberculosis may be more susceptible to ethambutol-induced optic neuropathy; this may be due to dependency on the kidney for excretion. [1]", "contents": "Ethambutol -- Adverse Effects -- Loss of Visual Acuity. Optic neuropathy/optic neuritis/retrobulbar neuritis Decreased visual acuity Scotoma Color blindness Visual field defect Blurred vision Peripheral neuropathy Hepatotoxicity Numbness and tingling of extremities due to peripheral neuritis Mental confusion, disorientation, and possible hallucinations Psychosis [15] [16] Patients with\u00a0impaired renal function from renal tuberculosis may be more susceptible to ethambutol-induced optic neuropathy; this may be due to dependency on the kidney for excretion. [1]"}
{"id": "article-21383_25", "title": "Ethambutol -- Adverse Effects -- Drug-Drug Interactions", "content": "Coadministration of ethambutol with aluminum hydroxide-containing antacids in patients with tuberculosis reduced mean serum concentrations and urinary excretion of ethambutol. [17] Avoid concurrent use of ethambutol with these antacids for at least 4 hours after administration.\u00a0The results of a recent study found that the effectiveness of ethambutol against tuberculosis was negatively affected by metformin and rosiglitazone. Combining these drugs could harm tuberculosis treatment, especially during the initial phase, as ethambutol is crucial. Therefore,\u00a0combined use is not advised in patients with tuberculosis receiving Directly Observed Therapy (DOT). Further research is needed to validate these findings. [18]", "contents": "Ethambutol -- Adverse Effects -- Drug-Drug Interactions. Coadministration of ethambutol with aluminum hydroxide-containing antacids in patients with tuberculosis reduced mean serum concentrations and urinary excretion of ethambutol. [17] Avoid concurrent use of ethambutol with these antacids for at least 4 hours after administration.\u00a0The results of a recent study found that the effectiveness of ethambutol against tuberculosis was negatively affected by metformin and rosiglitazone. Combining these drugs could harm tuberculosis treatment, especially during the initial phase, as ethambutol is crucial. Therefore,\u00a0combined use is not advised in patients with tuberculosis receiving Directly Observed Therapy (DOT). Further research is needed to validate these findings. [18]"}
{"id": "article-21383_26", "title": "Ethambutol -- Contraindications", "content": "Patients need screening for contraindications to ethambutol. These\u00a0contraindications would include patients incapable of noting visual symptoms, such as those with dementia, mental retardation, and children due to ethambutol-induced optic neuropathy. Other\u00a0contraindications\u00a0are patients with pre-existing ophthalmological diseases due to the\u00a0ocular toxicity of ethambutol. [1] Contraindications also include hypersensitivity\u00a0to ethambutol in patients.", "contents": "Ethambutol -- Contraindications. Patients need screening for contraindications to ethambutol. These\u00a0contraindications would include patients incapable of noting visual symptoms, such as those with dementia, mental retardation, and children due to ethambutol-induced optic neuropathy. Other\u00a0contraindications\u00a0are patients with pre-existing ophthalmological diseases due to the\u00a0ocular toxicity of ethambutol. [1] Contraindications also include hypersensitivity\u00a0to ethambutol in patients."}
{"id": "article-21383_27", "title": "Ethambutol -- Monitoring", "content": "A dosing regimen of a daily dose of 25 mg/kg of body weight of ethambutol reaches a therapeutic range of 2 to 6 mcg/mL in serum 2 hours after administration. [19] Serum levels of\u00a0ethambutol\u00a0decrease to undetectable levels by 24 hours, except for some patients with impaired renal function.", "contents": "Ethambutol -- Monitoring. A dosing regimen of a daily dose of 25 mg/kg of body weight of ethambutol reaches a therapeutic range of 2 to 6 mcg/mL in serum 2 hours after administration. [19] Serum levels of\u00a0ethambutol\u00a0decrease to undetectable levels by 24 hours, except for some patients with impaired renal function."}
{"id": "article-21383_28", "title": "Ethambutol -- Monitoring", "content": "Ethambutol may cause ocular toxicity, which may be related to the dose and duration of the treatment. If signs indicate such an effect, immediate discontinuation of the drug is required. However, reports of cases of irreversible blindness exist. Due to the adverse effect of ethambutol-associated optic neuropathy, visual acuity tests such as baseline visual acuity, color vision, and a Humphrey visual field should be performed periodically when administering\u00a0the treatment during the regimen. [1] Hepatotoxicity is a common adverse effect of antitubercular treatments. Hence, both baseline and periodic hepatic function require assessment.", "contents": "Ethambutol -- Monitoring. Ethambutol may cause ocular toxicity, which may be related to the dose and duration of the treatment. If signs indicate such an effect, immediate discontinuation of the drug is required. However, reports of cases of irreversible blindness exist. Due to the adverse effect of ethambutol-associated optic neuropathy, visual acuity tests such as baseline visual acuity, color vision, and a Humphrey visual field should be performed periodically when administering\u00a0the treatment during the regimen. [1] Hepatotoxicity is a common adverse effect of antitubercular treatments. Hence, both baseline and periodic hepatic function require assessment."}
{"id": "article-21383_29", "title": "Ethambutol -- Monitoring", "content": "Patients receiving iron overload may need prolonged treatment or added bactericidal drugs to their regimen. One study showed that iron loading negatively affected the bactericidal properties of isoniazid (INH) and ethambutol. The excess iron limits the bactericidal effects of INH and completely inhibits that of ethambutol. Although this study focused on murine tuberculosis, clinical implications\u00a0for HIV-positive patients with lower CD4+ cells may exist but may also have certain degrees of iron loading or patients with haptoglobin 2-2 genotype. Due to the adverse effects of excess iron, patients who have these conditions may need to consider a more prolonged treatment and/or add bactericidal drugs to their regimen against tuberculosis. [20]", "contents": "Ethambutol -- Monitoring. Patients receiving iron overload may need prolonged treatment or added bactericidal drugs to their regimen. One study showed that iron loading negatively affected the bactericidal properties of isoniazid (INH) and ethambutol. The excess iron limits the bactericidal effects of INH and completely inhibits that of ethambutol. Although this study focused on murine tuberculosis, clinical implications\u00a0for HIV-positive patients with lower CD4+ cells may exist but may also have certain degrees of iron loading or patients with haptoglobin 2-2 genotype. Due to the adverse effects of excess iron, patients who have these conditions may need to consider a more prolonged treatment and/or add bactericidal drugs to their regimen against tuberculosis. [20]"}
{"id": "article-21383_30", "title": "Ethambutol -- Toxicity -- Signs and Symptoms of Toxicity", "content": "One of the most well-known adverse effects is optic neuritis. The effect of neuritis is dose-related, with greater than 40% of adults developing toxicity at doses greater than 50 mg/kg and around 0% to 3% of adults developing toxicity at 15 mg/kg/daily. [21] Currently, unknown protocols detect subclinical ethambutol-induced ocular toxicity. The results of a study in Korea conducted various visual tests such as color vision tests, retinal nerve fiber layer optical coherence tomography tests, and pattern visual evoked potential tests. The\u00a0results showed that\u00a0retinal nerve fiber layer optical coherence tomography tests and pattern\u00a0visual evoked potential tests\u00a0were promising as they could detect changes in visual patterns after\u00a06 months, while other tests in visual acuity, color vision, or visual fields showed no significant changes. [22]", "contents": "Ethambutol -- Toxicity -- Signs and Symptoms of Toxicity. One of the most well-known adverse effects is optic neuritis. The effect of neuritis is dose-related, with greater than 40% of adults developing toxicity at doses greater than 50 mg/kg and around 0% to 3% of adults developing toxicity at 15 mg/kg/daily. [21] Currently, unknown protocols detect subclinical ethambutol-induced ocular toxicity. The results of a study in Korea conducted various visual tests such as color vision tests, retinal nerve fiber layer optical coherence tomography tests, and pattern visual evoked potential tests. The\u00a0results showed that\u00a0retinal nerve fiber layer optical coherence tomography tests and pattern\u00a0visual evoked potential tests\u00a0were promising as they could detect changes in visual patterns after\u00a06 months, while other tests in visual acuity, color vision, or visual fields showed no significant changes. [22]"}
{"id": "article-21383_31", "title": "Ethambutol -- Toxicity -- Management of Toxicity", "content": "The manifestation of ethambutol-induced optic neuropathy appears to be from\u00a0the chelation of copper. A study with 60 patients undergoing treatment with ethambutol monitored their serum copper levels. Statistical analysis confirmed a significant change in copper concentration, supporting the copper chelation effect. [23] An in-vitro study suggests that therapeutic copper can potentially prevent ethambutol-induced optic neuropathy while not compromising\u00a0the bacteriostatic properties. [24] Patients who experience any visual symptoms should discontinue the drug immediately and consult their doctor. [25]", "contents": "Ethambutol -- Toxicity -- Management of Toxicity. The manifestation of ethambutol-induced optic neuropathy appears to be from\u00a0the chelation of copper. A study with 60 patients undergoing treatment with ethambutol monitored their serum copper levels. Statistical analysis confirmed a significant change in copper concentration, supporting the copper chelation effect. [23] An in-vitro study suggests that therapeutic copper can potentially prevent ethambutol-induced optic neuropathy while not compromising\u00a0the bacteriostatic properties. [24] Patients who experience any visual symptoms should discontinue the drug immediately and consult their doctor. [25]"}
{"id": "article-21383_32", "title": "Ethambutol -- Enhancing Healthcare Team Outcomes", "content": "Ethambutol-induced optic neuropathy is a well-known disease that can be irreversible but is preventable. Timely and appropriate screenings are important in determining the outcome of the patient.\u00a0According to epidemiologic studies investigating this neuropathy, between 0.7% and 1.29% of patients showed a prevalence of optic neuropathy when taking the World Health Organization (WHO) recommended dosages. Optical coherence tomography\u00a0demonstrated a clinically significant decrease in the thickness of the retinal nerve fiber layer. [26] Ethambutol-induced optic neuropathy is a well-known adverse effect of treatment; all patients on ethambutol should be screened regularly by ophthalmologists. [25]", "contents": "Ethambutol -- Enhancing Healthcare Team Outcomes. Ethambutol-induced optic neuropathy is a well-known disease that can be irreversible but is preventable. Timely and appropriate screenings are important in determining the outcome of the patient.\u00a0According to epidemiologic studies investigating this neuropathy, between 0.7% and 1.29% of patients showed a prevalence of optic neuropathy when taking the World Health Organization (WHO) recommended dosages. Optical coherence tomography\u00a0demonstrated a clinically significant decrease in the thickness of the retinal nerve fiber layer. [26] Ethambutol-induced optic neuropathy is a well-known adverse effect of treatment; all patients on ethambutol should be screened regularly by ophthalmologists. [25]"}
{"id": "article-21383_33", "title": "Ethambutol -- Enhancing Healthcare Team Outcomes", "content": "Although ethambutol\u00a0is a bacteriostatic agent used to prevent the emergence of drug resistance to other first-line drugs, ethambutol-resistant strains are recognized.\u00a0With the rise of drug-resistant strains of TB and the current 6-month regimen of\u00a04 drugs that can potentially expand to 18\u00a0to 24 months, leading to inadequate compliance and poor outcomes, a search for different treatments persists. Completion of and compliance with the anti-tuberculosis regimen are of paramount importance to treating patients with TB and controlling TB globally. [27] The development of new drugs such as bedaquiline, pretomanid, delamanid, and bedaquiline\u00a0to combat these challenges can have significant impacts on the way tuberculosis is treated and transmitted. [5] [28]", "contents": "Ethambutol -- Enhancing Healthcare Team Outcomes. Although ethambutol\u00a0is a bacteriostatic agent used to prevent the emergence of drug resistance to other first-line drugs, ethambutol-resistant strains are recognized.\u00a0With the rise of drug-resistant strains of TB and the current 6-month regimen of\u00a04 drugs that can potentially expand to 18\u00a0to 24 months, leading to inadequate compliance and poor outcomes, a search for different treatments persists. Completion of and compliance with the anti-tuberculosis regimen are of paramount importance to treating patients with TB and controlling TB globally. [27] The development of new drugs such as bedaquiline, pretomanid, delamanid, and bedaquiline\u00a0to combat these challenges can have significant impacts on the way tuberculosis is treated and transmitted. [5] [28]"}
{"id": "article-21383_34", "title": "Ethambutol -- Enhancing Healthcare Team Outcomes", "content": "Pharmacies are crucial in\u00a0TB control, especially in high-burden countries. However, they often face challenges in providing quality care, including the availability of anti-TB drugs and patient management. Interventions, such as public-private mix initiatives, aim to improve case detection by training pharmacists to refer symptomatic patients for testing. Ethambutol, a key anti-TB drug, is often stocked, but quality assurance is essential. Future efforts should focus on expanding interventions to improve patient counseling and address inappropriate medication sales while establishing global pharmacy-specific guidelines and enhancing regulatory environments. [29]", "contents": "Ethambutol -- Enhancing Healthcare Team Outcomes. Pharmacies are crucial in\u00a0TB control, especially in high-burden countries. However, they often face challenges in providing quality care, including the availability of anti-TB drugs and patient management. Interventions, such as public-private mix initiatives, aim to improve case detection by training pharmacists to refer symptomatic patients for testing. Ethambutol, a key anti-TB drug, is often stocked, but quality assurance is essential. Future efforts should focus on expanding interventions to improve patient counseling and address inappropriate medication sales while establishing global pharmacy-specific guidelines and enhancing regulatory environments. [29]"}
{"id": "article-21383_35", "title": "Ethambutol -- Enhancing Healthcare Team Outcomes", "content": "Given ethambutol's toxicity profile, the decision to\u00a0treat tuberculosis cases should involve an interprofessional team, including infectious disease specialists. Close monitoring of the patient, careful assessment of the medication profile, and determining the susceptibility of the infection are all key factors in charting the therapeutic course. An interprofessional team approach and open communication between infectious disease specialists, nurse practitioners, physician assistants, pharmacists, and ophthalmologists are necessary to\u00a0optimize patient outcomes with\u00a0ethambutol therapy.", "contents": "Ethambutol -- Enhancing Healthcare Team Outcomes. Given ethambutol's toxicity profile, the decision to\u00a0treat tuberculosis cases should involve an interprofessional team, including infectious disease specialists. Close monitoring of the patient, careful assessment of the medication profile, and determining the susceptibility of the infection are all key factors in charting the therapeutic course. An interprofessional team approach and open communication between infectious disease specialists, nurse practitioners, physician assistants, pharmacists, and ophthalmologists are necessary to\u00a0optimize patient outcomes with\u00a0ethambutol therapy."}
{"id": "article-21383_36", "title": "Ethambutol -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Ethambutol -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}